CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics; New Report Launched
This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the...
View full press release